Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Indaptus Therapeutics ( (INDP) ) has shared an announcement.
On December 29, 2025, Indaptus Therapeutics, Inc. announced that three members of its Board of Directors — Michael Newman, Mark Gilbert and Anthony Maddaluna — submitted their resignations, to be effective upon the approval of David Lazar’s nominees at the company’s next stockholders’ meeting. The company stated that these resignations were not due to any disagreement with management, the board or its committees regarding the company’s operations, policies or practices, indicating an orderly governance transition rather than a response to internal conflict.
The most recent analyst rating on (INDP) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Neutral.
The score is primarily held down by weak financial performance (pre-revenue, persistent losses, and negative cash flow alongside shrinking assets/equity). Technicals are only modestly supportive with mixed trend signals, and valuation metrics provide limited support due to negative earnings and no dividend yield data.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Average Trading Volume: 812,388
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.1M
For an in-depth examination of INDP stock, go to TipRanks’ Overview page.